Any current/future new fundraising through debt or equity?

The company does not mention any plans for new fundraising through debt or equity in the transcript. The focus is on deleveraging and reducing existing debt by recovering government receivables and using internal accruals for growth. Current cost of borrowing is around 9.7%, and significant reduction through refinancing is not expected; debt reduction will primarily come from repayments. Management aims to bring down promoter pledges to zero over the next year or so. Growth is to be funded through internal cash flows rather than fresh external funding. No indication of immediate or future fres

Any current/future capex/capital investment/strategic investment?

Current capex for the fiscal year was about INR 225 crores, slightly lower than depreciation (INR 242 crores). Most of the capex is maintenance; a small part is growth-oriented. Similar capex trends are expected for FY '25, implying maintenance-heavy investment with modest growth capex. Capacity utilization is currently around 50-55%, and the company believes it can double business over the next few years without much additional capex, mostly requiring maintenance and small growth capex. No significant net capex planned; focus appears to be on better utilization of existing capacities. Strateg

Future growth expectations in sales/revenue/volumes?

The company is targeting to double its revenue in the next 4 years. Retail business grew by 25% this year and is expected to continue growing north of 20% annually without further investment in receivables. Medium-term vision (2-3 years) is bullish on growth in 3-4 key segments including drip and sprinkler irrigation. The food business aims to grow at a double-digit rate (~15%) in FY '25, up from 5-6% growth in FY '24. Tissue culture business showed strong growth (from INR177 crores to INR250 crores) and is expected to grow faster, targeting INR1,000 crores over the next 5-6 years. C

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets double-digit revenue growth for FY '25, with potential to double revenue over the next 4 years. EBITDA margin is aimed to improve, targeting around 15% in the medium term, though full-year 15% for FY '25 is ambitious. Free cash flow improvement and deleveraging are key priorities, with substantial debt reduction expected as government projects close. Retail business growth is strong at 25%, driving earnings improvements with better cost absorption and stable receivables (26 days). Tissue culture business shows rapid growth (INR177 crore to INR250 crore), expected to

Current/ Expected Orderbook/ Pending Orders?

Current food business order book in India: approximately INR 335 crores. Global consolidated food business order book: about INR 1,000 crores. Non-food business order inflows occur continuously through dealer orders; no large accumulated order book. Project business order book (non-food): around INR 900 crores, largely institutional contractor business and existing government project business. Outstanding government projects to be completed: about INR 200-250 crores, targeted to close by FY '26. Post FY '25, company plans to reduce direct government exposure, supplying pipes/drip systems throu

Jain Irrigation Systems LtdQ1 FY25

Jain Irrigation Systems Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹26.5Market Cap: ₹2.3K Cr

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company is targeting to double its revenue in the next 4 years.
→Retail business grew by 25% this year and is expected to continue growing north of 20% annually without further investment in receivables.
→Medium-term vision (2-3 years) is bullish on growth in 3-4 key segments including drip and sprinkler irrigation.
→The food business aims to grow at a double-digit rate (~15%) in FY '25, up from 5-6% growth in FY '24.
→Tissue culture business showed strong growth (from INR177 crores to INR250 crores) and is expected to grow faster, targeting INR1,000 crores over the next 5-6 years.
→Capital utilization is currently about 50-55%, with potential to double revenues without significant capex.
→Government projects winding down; retail and institutional sales through dealers expected to drive future growth.
→Positive demand outlook supported by value-added agriculture and direct benefit transfers to farmers.

Margin guidance

Category 2

→The company targets double-digit revenue growth for FY '25, with potential to double revenue over the next 4 years.
→EBITDA margin is aimed to improve, targeting around 15% in the medium term, though full-year 15% for FY '25 is ambitious.
→Free cash flow improvement and deleveraging are key priorities, with substantial debt reduction expected as government projects close.
→Retail business growth is strong at 25%, driving earnings improvements with better cost absorption and stable receivables (26 days).
→Tissue culture business shows rapid growth (INR177 crore to INR250 crore), expected to contribute significantly to future profitability.
→Overseas plastic sheet business and food processing segments are also expected to grow, supporting margin expansion.
→FY '25 is anticipated to be a steady growth year, barring election-related or monsoon uncertainties, with overall healthier profit generation.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company does not mention any plans for new fundraising through debt or equity in the transcript.
→The focus is on deleveraging and reducing existing debt by recovering government receivables and using internal accruals for growth.
→Current cost of borrowing is around 9.7%, and significant reduction through refinancing is not expected; debt reduction will primarily come from repayments.
→Management aims to bring down promoter pledges to zero over the next year or so.
→Growth is to be funded through internal cash flows rather than fresh external funding.
→No indication of immediate or future fresh equity raise was mentioned; the company is concentrating on reducing leverage and improving capital utilization.

Order book

→Current food business order book in India: approximately INR 335 crores.
→Global consolidated food business order book: about INR 1,000 crores.
→Non-food business order inflows occur continuously through dealer orders; no large accumulated order book.
→Project business order book (non-food): around INR 900 crores, largely institutional contractor business and existing government project business.
→Outstanding government projects to be completed: about INR 200-250 crores, targeted to close by FY '26.
→Post FY '25, company plans to reduce direct government exposure, supplying pipes/drip systems through third parties with secured financing.
→Retail business operates on a cash-and-carry model with no formal order book; orders renew monthly.
→Tissue culture business receives advances from farmers, which are included as part of the order book.

Capex plans

Yes

→Current capex for the fiscal year was about INR 225 crores, slightly lower than depreciation (INR 242 crores).
→Most of the capex is maintenance; a small part is growth-oriented.
→Similar capex trends are expected for FY '25, implying maintenance-heavy investment with modest growth capex.
→Capacity utilization is currently around 50-55%, and the company believes it can double business over the next few years without much additional capex, mostly requiring maintenance and small growth capex.
→No significant net capex planned; focus appears to be on better utilization of existing capacities.
→Strategic investment focus includes building distribution networks in new agricultural and non-agricultural piping segments, especially targeting rural areas and new applications like plumbing and drainage aligned with Swachh Bharat initiatives.
→Moving forward, company aims to shift government project exposure away and grow retail and institutional business segments.

How does Jain Irrigation Systems Ltd rank vs peers in ?

Pro feature

1Jain Irrigation Systems Ltd

Rev 3Mar 2

See full sector rankings

Want more stocks like Jain Irrigation Systems Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio